Citations

Clear

590 citation(s) found for "Ho, Ben".

Rare but Relevant? Assessing Variants in Dystonia‐Linked Genes in Parkinson's Disease
Screven, Laurel A. , Tan, Ai Huey , Fenn, Matilda, Frost, Joshua L.I., Jankovic, Joseph, Jasaityte, Simona , Jeon, Beomseok , Sarmiento, Ignacio Juan Keller , Krüger, Rejko , Kuhlenbäumer, Gregor , Schirinzi, Tommaso , Shulman, Joshua M., Uitti, Ryan J. , Wu, Lesley , Zeuner, Kirsten E., Blauwendraat, Cornelis , Singleton, Andrew, Lohmann, Katja , (GP2), the Global Parkinson's Genetics Program, Tan, Ai Huey , Jeon, Beom Seok , Lin, Chin-Hsien , Schirinzi, Tommaso , Shin, Jung Hwan , Tay, Yi Wen , Uitti, Ryan, Warner, Thomas T. , Wszolek, Z.K. , Wu, Ruey-Meei , Blauwendraat, Cornelis , Morris, Huw R , Lohmann, Katja , Lange, Lara Mariah , Fang, Zih‐Hua , Alcalay, Roy N. , Amouri, Rim , Bovenzi, Roberta , Frost, Joshua L.I., Jankovic, Joseph J. , Jaunmuktane, Zane , Lin, Chin‐Hsien , Pavelka, Lukas , Periñán, María Teresa , Sassi, Samia Ben , Shulman, Joshua M. , Wszołek, Zbigniew K. , Wu, Ruey‐Meei , Singleton, Andrew , Mencacci, Niccolò Emanuele , Morris, Huw R. , Lim, Shen‐Yang , Klein, Christine , (GP2), the Global Parkinson's Genetics Program

Mayo Clinic

Movement Disorders | October 11, 2025 | Volume: 41 | Issue: 1 | Pages: 247-259

10.1002/mds.70073 | PMID 41074695 Get It

Abstract Background Dystonia and Parkinson's disease (PD) exhibit clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective The aim was to assess the frequency of dystonia‐linked pathogenic variants in PD. Methods We screened sequencing data from 15,684 individuals (8272 PD, 3200 atypical parkinsonism, and 4212 unaffected) from the Global Parkinson's Genetics Program (GP2) and Accelerating Medicines Partnership‐Parkinson's Disease (AMP‐PD) for variants in genes linked to isolated dystonia, dystonia‐parkinsonism, and myoclonus‐dystonia. Results Pathogenic variants were identified only in PD patients. Forty‐five PD individuals (0.54%) carried 26 distinct (likely) pathogenic variants in nine dystonia‐linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion Though rare, pathogenic variants in dystonia‐linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD‐relevant gene with clinical implications, whereas variants identified in other genes are rare and of uncertain relation to the PD phenotype. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Multidisciplinary Atrial Fibrillation Clinics: A Model for Comprehensive Management
Abdelnabi, Mahmoud , Ashour, Firas , Rodriguez, Cristian , Puchongmart, Chanokporn , Thiravetyan, Ben , Cruz, Diego , Ibrahim, Ramzi , Habib, Eiad , Kanaan, Christopher , Arsanjani, Reza, Sorajja, Dan , Ibrahim, Ramzi , Pham, Hoang Nhat , Arsanjani, Reza

Mayo Clinic

Reviews in Cardiovascular Medicine | October 11, 2025 | Volume: 26 | Issue: 9 | Pages: No page available

10.31083/rcm38739 | PMID 41089805 Get It

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity, mortality, and healthcare expenses. Meanwhile, effective management of AF requires a comprehensive, patient-centered approach that includes risk factor modification, rate and rhythm control strategies, and prevention of thromboembolic events. Multidisciplinary AF clinics have emerged as a model for comprehensive management to improve patient outcomes and reduce healthcare burden. This review discusses the rationale, structure, benefits, challenges, and future directions of multidisciplinary AF clinics, emphasizing their role in optimizing AF management.
Heart Transplantation for Amyloid Cardiomyopathy Has Comparable Outcomes With Other Etiologies: The UNOS Database
Steudel, Nicholas , Doulamis, Ilias P. , Rastogi, Shivam, Tzani, Aspasia , Kuno, Toshiki, Alnsasra, Hilmi , Tepetes, Nikolaos, Kılıç, Ahmet , Briasoulis, Alexandros , Rastogi, Shivam, Kuno, Toshiki , Asleh, Rabea , Tepetes, Nikolaos-Iason , Avgerinos, Dimitrios V. , Briasoulis, Αlexandros

Mayo Clinic

Clinical Transplantation | October 9, 2025 | Volume: 39 | Issue: 10 | Pages: No page available

10.1111/ctr.70343 | PMID 41065067 Get It

ABSTRACT Background and Aim This study aimed to provide updated nationwide data on outcomes in heart transplantation for amyloid cardiomyopathy (ACM) compared with other cardiomyopathy etiologies. Methods United Network for Organ Sharing data for patients over 18 who underwent heart transplant for ACM, and other cardiomyopathies including DCM, ICM, RCM, and CHD were reviewed from 2001 through 2022. The data were analyzed with a propensity score‐matched analysis comparing ACM patients with transplant for the cardiomyopathies to measure primary outcomes, including 5‐year, 10‐year, and all‐cause mortality accounting for differences at baseline. Results Of 21 457 heart transplant recipients who met eligibility criteria, there was a 100% increase in the number of heart transplants for ACM from 2010 to 2020 ( p < 0.001). The unadjusted mortality did not differ significantly among ACM, DCM, ICM, RCM, and CHD groups, and 5‐year mortality was comparable between ACM and DCM patients. ACM patients had a significantly lower incidence of postoperative stroke ( p = 0.044), and risk factors for ACM transplant mortality were identified as mechanical ventilation at the time of transplant (HR: 3.8, p = 0.023) and older donor age (HR: 1.1, p = 0.015). Conclusions The number of heart transplants for ACM has increased in recent years, and overall outcomes in these ACM transplants have been similar compared to those for other cardiomyopathies. Despite historical concerns regarding poor prognosis and amyloid recurrence, carefully screened ACM patients can benefit from heart transplantation. Further research and optimization of ACM patient eligibility criteria alongside investigation of concurrent adjunctive therapies could optimize treatment of ACM with heart transplantation.
Robotic-Assisted Electromagnetic Guidance Improves Success of Percutaneous Access for Nephrolithotomy: A Study of Novices and Experts
Ballantyne, Christopher, Wymer, Kevin , Sehgel, Nancy L., Chew, Ben H. , Elkhoury, Fuad, Sivalingam, Sri , Dunn, Matthew D. , Borofsky, Michael S. , Humphreys, Mitchell R. , Ballantyne, Christopher C, Chew, Ben H

Mayo Clinic

Journal of Endourology | October 6, 2025 | Volume: 39 | Issue: 8 | Pages: 772-780

10.1177/08927790251368775 | PMID 40792637 Get It

Introduction: Percutaneous nephrolithotomy (PCNL) has been a mainstay treatment for large stone burdens since the 1980s, historically offering improved stone-free rates over retrograde intrarenal surgery (RIRS). Gaining optimal access into the renal collecting system can be challenging, requiring advanced skills or interventional radiology assistance. The learning curve for fluoroscopic and ultrasonography access can be steep, with only a minority of PCNL access performed by urologists in the United States. This study compares robotic-assisted electromagnetic (EM) guidance to traditional fluoroscopy for obtaining percutaneous renal access between cohorts of novice and expert urologists. Methods: Ten novices and five expert urologists used robotic-assisted EM guidance to obtain access in a modified supine position compared with using fluoroscopy in a traditional prone position in human cadavers. Primary success was defined as papillary access. Performance metrics, including number of puncture attempts, time to access, radiation exposure, and participant confidence, were compared between novices and experts. Results: Robotic-assisted EM guidance improved success rates for both novices (100% vs 70%) and experts (93% vs 87%) compared with fluoroscopy. Novices showed greater accuracy using robotic assistance (97% vs 37%). The number of insertion attempts decreased with robotic guidance for both groups (novices: 3.42 ± 0.44 vs 1.47 ± 0.19; experts: 2.13 ± 0.36 vs 1.40 ± 0.24; p < 0.002). EM guidance ( p < 0.05) and experience ( p < 0.05) significantly reduced the time from needle insertion to access (novices: 12.86 ± 2.41 minutes vs 4.49 ± 0.96 minutes; experts: 4.90 ± 1.40 minutes vs 4.09 ± 1.12 minutes). Radiation exposure was notably lower with EM guidance (novices, 1.12 ± 0.17 mGy vs 4.86 ± 0.70 mGy; experts, 0.69 ± 0.12 mGy vs 4.11 ± 1.21 mGy; p < 0.001). Novices felt more confident (5[3–5] vs 2[1–4], p < 0.001) and at ease (5[3–5] vs 2.75[1–3], p < 0.001) with EM guidance. Conclusion: Robotic-assisted EM guidance improves percutaneous access success, reduces attempts and radiation exposure, and enhances novice confidence and accuracy. This technology could enable urologists to more effectively and safely perform PCNL, especially for less experienced practitioners.
Supporting cancer research on real-world data: extracting colorectal cancer status and explicitly written TNM stages from free-text imaging and histopathology reports
Tamm, Andres , Jones, Helen , Doshi, Neel , Perry, William , Withers, Joshua, Salih, Hizni , Noble, Theresa , Little, Stephanie , Roadknight, Gail , Campell, D.J., Matharu, Sheila, Teare, Marion, Galdikas, A., Papadimitriou, Dimitri , Scanlon, Lauren , Woods, Kerrie , Cunningham, Chris , Roadknight, Gail , Perry, William R , Várnai, Kinga A. , Matharu, Sheila, Starling, Naureen , Teare, Marion, Galdikas, Algirdas, Glampson, Ben , Mercuri, Luca , Wasan, Harpreet , Malcomson, Lee , O’Hara, Catherine M. , Renehan, Andrew G. , Nicholson, Brian D , Davies, Jim , Morris, Eva J.A. , Cunningham, Chris

Mayo Clinic

BMJ Health & Care Informatics | September 22, 2025 | Volume: 32 | Issue: 1 | Pages: e101521

10.1136/bmjhci-2025-101521 | PMID 40983364 Get It

Objectives The ‘tumour, node, metastasis’ (TNM) classification of colorectal cancer (CRC) predicts prognosis and so is vital to consider in analyses of patterns and outcomes of care when using electronic health records. Unfortunately, it is often only available in free-text reports. This study aimed to develop regex-based text-processing algorithms that identify the reports describing CRC and extract the TNM staging at a low computational cost. Methods The CRC and TNM extraction algorithms were iteratively developed using 58 634 imaging and pathology reports of patients with CRC from the Oxford University Hospitals (OUH) and Royal Marsden (RMH) NHS Foundation Trusts (FT), with additional input from Imperial College Healthcare and Christie NHS FTs. The algorithms were evaluated on a stratified random sample of 400 OUH development data reports and 400 newer ‘unseen’ OUH reports. The reports were annotated with the help of two clinicians. Results The CRC algorithm achieved at least 93.0% positive predictive value (PPV), 72.1% sensitivity, 64.0% negative predictive value (NPV) and 90.1% specificity for primary CRC on pathology reports. On imaging reports, it demonstrated at least 78.0% PPV, 91.8% sensitivity, 93.0% NPV and 80.9% specificity. For the main T/N/M categories, the TNM algorithm achieved PPVs of at least 93.9% (T), 97.7% (N) and 97.2% (M), and sensitivities of 63.6% (T), 89.6% (N) and 64.8% (M). NPVs were at least 45.0% (T), 91.1% (N), 88.4% (M), and specificities 95.7% (T), 98.1% (N), 99.3% (M). Reductions in performance were mostly due to implicit staging. For extracting explicit TNM stages, current or historical, the algorithm made no errors on 400 pathology reports and six errors on 400 imaging reports. Conclusion The TNM algorithm accurately extracts explicit TNM staging, but other methods are needed for retrieving implicit stages. The CRC algorithm is accurate on non-supplementary reports, but outputs need additional review if higher precision is required.
A Neurosurgeon's Guide to Mobile Health Application Development With a Case Study for Cervical Myelopathy
Singh, Pranay , Chen, Erdong, Steel, Ben , Chicoine, Nicolas, Yakdan, Salim, Bydon, Mohamad, Steinmetz, Michael P. , Ray, Wilson Z. , Johnson, Brian P. , Duncan, Ryan P. , Wilt, Zachary , Kelleher, Caitlin , Greenberg, Jacob K , Chen, Erdong, Steel, Benjamin, Yakdan, Salim M. , Bydon, Mohamad , Ghogawala, Zoher , Badhiwala, Jetan H.

Mayo Clinic

Neurosurgery | September 9, 2025 | Volume: 98 | Issue: 4 | Pages: 726-736

10.1227/neu.0000000000003717 | PMID 40923792 Get It

The integration of mobile health (mHealth) technologies is transforming neurosurgery. Despite its potential, many uses remain unrealized due to the unique challenges and complexity of developing mHealth technology. While neurosurgeons bring invaluable clinical expertise and an understanding of patient needs, the technical intricacies of application development often require collaboration with developers and computer scientists, a process that can feel unfamiliar and difficult to navigate. The aim of this article was to demystify mHealth development by providing a guide for neurosurgeons seeking to develop disease-specific mHealth applications. We outline this process using the development of SynapTrack, an mHealth tool designed to provide objective assessments of degenerative cervical myelopathy, a chronic condition caused by symptomatic compression of the cervical spinal cord. This article offers neurosurgeons concrete guidance on navigating key considerations such as design decisions, algorithm integration, database architecture, and data security. By grounding these insights with SynapTrack, this guide offers a transparent view into the development process and provides a practical framework that can be adapted to the development of other mHealth tools. The aim of this work was to foster interdisciplinary collaboration and enable neurosurgeons to develop mHealth applications tailored to the specific needs of their specialty.
Artificial intelligence in valvular heart disease: current evidence and future perspectives
Suc, Gaspard , Sengupta, Partho P. , Ali, Walid Ben , Piazza, Nicolò , Burwash, Ian G. , Theriault‐Lauzier, Pascal , Avram, Robert , Bruce, Charles J. , Bohbot, Yohann , Dreyfus, Julien , Enriquez‐Sarano, Maurice , Modine, Thomas , Messika–Zeitoun, David

Mayo Clinic

European Heart Journal - Valvular and Structural Heart Disease | September 8, 2025 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/ehjvshd/xwaf002 Get It

Abstract Valvular heart disease (VHD) is emerging as the next major epidemic in cardiovascular care, driven by the ageing population. The advent of less invasive alternatives to surgery—namely, transcatheter therapies—has revolutionized patient management, while simultaneously introducing new layers of complexity. Artificial intelligence (AI) holds significant promise to transform the care of patients with VHD across all dimensions, including diagnosis, prognostication, disease progression, and therapeutic decision-making. In this review, we provide a comprehensive overview of the current evidence, and discuss the challenges, risks, and future directions associated with the integration of AI in the management of VHD.
Modifying inhibitor specificity for homologous enzymes by machine learning
Gozlan, Dor S. , Meiri, Reut , Shapira, Gili, Radisky, Evette S. , Orenstein, Yaron , Papo, Niv , Coban, Matt , Radisky, Evette S , Orenstein, Yaron , Papo, Niv , Shapira, Gili

Mayo Clinic

The FEBS Journal | September 6, 2025 | Volume: 293 | Issue: 4 | Pages: 1007-1023

10.1111/febs.70249 | PMID 40912922 Get It

Selective inhibitors are essential for targeted therapeutics and for probing enzyme functions in various biological systems. The two main challenges in identifying such protein‐based inhibitors lie in the extensive experimental effort required, including the generation of large libraries, and in tailoring the selectivity of inhibitors to enzymes with homologous structures. To address these challenges, machine learning (ML) is being used to improve protein design by training on targeted libraries and identifying key interface mutations that enhance affinity and specificity. However, such ML‐based methods are limited by inaccurate energy calculations and difficulties in predicting the structural impacts of multiple mutations. Here, we present an ML‐based method that leverages HTS data to streamline the design of selective protease inhibitors. To demonstrate its utility, we applied our new method to find inhibitors of matrix metalloproteinases (MMPs), a family of homologous proteases involved in both physiological and pathological processes. By training ML models on binding data for three MMPs (MMP‐1, MMP‐3, and MMP‐9), we successfully designed a novel N‐TIMP2 variant with a differential specificity profile, namely, high affinity for MMP‐9, moderate affinity for MMP‐3, and low affinity for MMP‐1. Our experimental validation showed that this novel variant exhibited a significant specificity shift and enhanced selectivity compared with wild‐type N‐TIMP2. Through molecular modeling and energy minimization, we obtained structural insights into the variant's enhanced selectivity. Our findings highlight the power of ML‐based methods to reduce experimental workloads, facilitate the rational design of selective inhibitors, and advance the understanding of specific inhibitor–enzyme interactions in homologous enzyme systems.
Triple A Plus ( AAA + ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
Tefferi, Ayalew , Loscocco, Giuseppe Gaetano , Rokach, Lior , Tadmor, Tamar , Faldu, Priyansh, Melamed, Guy , Alapi, Hilel, Abdelmagid, Maymona, Abdelaziz, Rania M., Yousuf, Muhammad , Nakhleh, Merry , Pardanani, Animesh , Begna, Kebede H. , Patnaik, Mrinal M. , Barbui, Tiziano , Reichard, Kaaren K. , He, Rong , Gangat, Naseema , Loscocco, Giuseppe Gaetano , Patnaik, Mrinal , Szuber, Natasha , He, Rong , Guglielmelli, Paola , Gangat, Naseema , Vannucchi, Alessandro M , Abdelaziz, Rania M., Szuber, Natasha , Carobbio, Alessandra , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | September 3, 2025 | Volume: 100 | Issue: 11 | Pages: 2017-2027

10.1002/ajh.70065 | PMID 40899793 Get It

ABSTRACT Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple‐A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC) and lymphocyte (ALC) counts as risk variables. In the current study, a Mayo Clinic discovery cohort of 658 patients with ET was used to identify AAA‐independent risk variables. Accordingly, multivariable analysis‐derived HRs (95% CI) were 15.7 (8.4–29.5) for age > 70 years (8 points); 4.2 (2.3–7.5) for age 50 to 70 years (2 points); 1.8 (1.2–2.5) for ANC ≥ 8 × 10 9 /L (1 point); 1.4 (1.03–1.9) for ALC < 1.7 × 10 9 /L (1 point); 1.8 (1.2–2.6) for absolute monocyte count (AMC) ≥ 0.5 × 10 9 /L (1 point); 1.8 (1.2–2.3) for male sex (1 point); 1.8 (1.3–2.4) for arterial hypertension (1 point); and 1.6 (1.2–2.3) for arterial thrombosis (1 point). HR‐weighted scoring enabled a 4‐tiered risk classification: ultra‐low (0–1 points; N = 94; median survival 42.7 years), low (2–4 points; N = 297; 23 years), intermediate (5 points; N = 66; 17.3 years), and high (6–14 points; N = 201; 10.8 years). Time‐dependent predictive performance at 20/25 years favored AAA + (AUC 0.92/0.91) vs. AAA (0.86/0.86) vs. IPSET (0.81/0.84). The AAA + risk model was subsequently validated by two external cohorts from Israel ( N = 5968) and Italy ( N = 682). In the cohort from Israel, disease‐specific mortality was assessed by comparing observed survival to an age‐ and sex‐matched reference population, which suggested near‐normal life expectancy in ultra‐low risk patients. The current study highlights host‐related factors as the primary determinants of longevity in ET and provides a composite risk score (AAA + ) that is based on complete blood count‐derived parameters and host‐related factors. Predictive performance of the new model was shown to be superior to that of IPSET and AAA.
European‐based polygenic risk score and genome‐wide association study of B‐cell non‐Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs
Kleinstern, Geffen , Robinson, Dennis P. , Perlman, Riki , Jebrini, Nidal, Elyan, Hussein, Yehuda, Dina Ben , Paltiel, Ora , Paltiel, Ora , Seir, Rania Abu , Liu, Jianjun , Elyan, Hussein, Slager, Susan L.

Mayo Clinic

British Journal of Haematology | August 31, 2025 | Volume: 207 | Issue: 5 | Pages: 1832-1841

10.1111/bjh.70125 | PMID 40887045 Get It

Summary Among individuals of European Ancestry (EA), genome‐wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) and polygenic risk scores (PRSs) associated with non‐Hodgkin lymphoma (NHL) risk. We evaluated subtype‐specific PRSs, based on established EA‐SNPs, in Israeli Jews (IJ) and Palestinian Arabs (PA) and performed a GWAS in the combined ethnic groups to identify new loci. We included three common pathologically confirmed subtypes: diffuse large B‐cell (DLBCL), follicular (FL) and marginal zone (MZL) lymphomas. Controls were frequency matched to cases by age and sex. Among 752 IJ (201—DLBCL; 130—FL; 54—MZL/367—controls) and 593 PA (203—DLBCL; 41—FL/349‐controls), we computed PRSs weighted by EA‐derived effect estimates and used logistic regression models adjusted for confounders. In the combined ethnic groups of IJ and PA, subtype‐specific PRSs were significantly associated with the corresponding subtype, with a 1.69‐fold, 2.21‐fold and 2.26‐fold risk for DLBCL, FL and MZL, respectively; however, these effect sizes were attenuated compared to those reported in EA and varied by ethnicity. In the GWAS of the combined ethnic groups, two novel SNPs in the 6p21.32 locus were associated with DLBCL risk. Additional GWAS studies are needed among Jewish and Arab populations to improve genetic risk prediction for NHL in these ethnic groups.